All currency values in $ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 ~2.2:1 split | DEC 2024 14:1 split | DEC 2023 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | $0 | $0 | $0 | $33 |
| General & Administrative | $17 | $20 | $17 | $14 |
| Research & Development | $50 | $70 | $50 | $50 |
| Total Operating Expenses | $68 | $90 | $68 | $64 |
| Operating Income | -$67 | -$90 | -$67 | -$31 |
| Non-Operating | ||||
| Net Interest Expense | $5 | $6 | $5 | $3 |
| Other Non-Operating Income (Expense) | $2 | $6 | -$3 | -$1 |
| EBT (Earnings Before Tax) | – | – | -$65 | -$29 |
| Income Tax Expense | – | $0 | $0 | $0 |
| Net Income | ||||
| Net Income | -$65 | -$84 | -$65 | -$29 |
| Per Share Data | ||||
| Revenue Per Share | $0.02 | $0.00 | $0.02 | $41.72 |
| EPS (Basic) | -$5.81 | -$3.43 | -$5.81 | -$35.78 |
| EPS (Diluted) | -$5.81 | -$3.43 | -$5.81 | -$35.78 |
| Weighted Avg Shares (Basic) | 11.3M | 24.4M | 11.3M | 802,747 |
| Weighted Avg Shares (Diluted) | 11.3M | 24.4M | 11.3M | 802,747 |
| Shares Outstanding | 11.3M | 24.4M | 11.3M | 802,747 |
Artiva Biotherapeutics (ARTV) financials: revenue, profit and margins
Artiva Biotherapeutics (ARTV) generated about n/a in revenue and -$91 million in net income over the trailing twelve months, growing at roughly -99.3% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Artiva Biotherapeutics profitable?+
Artiva Biotherapeutics reported about -$91 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Artiva Biotherapeutics growing?+
Artiva Biotherapeutics's revenue has compounded at roughly -99.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ARTV's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ARTV
Held by ETFs
ARTV is in 3 US ETFs. The largest of them, with ARTV's weight in each:
Spot a number that looks wrong? Check it in ARTV's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ARTV
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.